FVFrançois Ventura

François Ventura

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


François Ventura has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Gilbert Greub

    Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland

    1 shared publication
  • Pierre Tissieres

    IHU-SEPSIS Comprehensive Sepsis Centre and Paediatric Intensive Care, Neonatal Medicine, and Paediatric Emergency Department, AP-HP Paris Saclay University, Bicêtre Hospital, 94275 Le Kremlin-Bicêtre, France; Institute of Integrative Biology of the Cell, CNRS, CEA, and Paris Saclay University, Gif-sur-Yvette, France

    1 shared publication
  • Shevin T. Jacob

    Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

    1 shared publication
  • Wayne Conrad Liles

    Sepsis Center of Research Excellence, University of Washington, Seattle, WA 98195-6420, USA

    1 shared publication

Latest Publications

  • Open Access

    The Possible Pathophysiological Role of Pancreatic Stone Protein in Sepsis and Its Potential Therapeutic Implication

    by François Ventura, Pierre Tissières

    According to the current understanding of the pathophysiology of sepsis, key host dysregulated responses leading to organ failure are mediated by innate immunity, through interactions between pathogen-associated molecular patterns (PAMPs) and damaged-associated molecular patterns (DAMPs) binding to four types of pattern recognition receptors (PRRs). PRRs activation triggers the protein kinase cascade, initiating the cellular response seen during sepsis. Pancreatic stone protein (PSP), a C-type lectin protein, is a well-defined biomarker of sepsis. Studies have shown that stressed and immune-activated pancreatic β-cells secrete PSP. Animal studies have shown that PSP injection aggravates sepsis, and that the disease severity score and mortality were directly correlated with the doses of PSP injected. In humans, studies have shown that PSP activates polymorphonuclear neutrophils (PMNs) and aggravates multiple organ dysfunction syndrome. Clinical studies have shown that PSP levels are correlated with disease severity, vasopressor support, progression to organ failure, mechanical ventilation, renal replacement therapy, length of stay, and mortality. As PSP is a C-type lectin protein, it may have a role in activating innate immunity through the C-type lectin receptors (CLRs), which is one of the four PRRs. Herein, we review the literature on PSP and its possible role in the pathophysiology of sepsis, and we discuss its potential therapeutic role.


  • Open Access

    Proposed Framework for Conducting Clinically Relevant Translational Biomarker Research for the Diagnosis, Prognosis and Management of Sepsis

    by François Ventura, Gilbert Greub, W. Conrad Liles, Shevin T. Jacob

    Although the diagnosis of sepsis requires the identification of the three components of infection, a systemic inflammation response, and organ dysfunction, there is currently no consensus on gold-standard criteria. There are however suggested tools and tests, which have been proposed in international guidelines, including those produced by the Surviving Sepsis Campaign. Biomarkers play an important role in these tools and tests, and numerous heterogeneous studies have been performed to evaluate their respective clinical utility. Our review of the current practice shows that no biomarkers of infection, systemic inflammation response, organ dysfunction and sepsis are currently specifically recommended, which is probably due to the lack of standardization of studies. We therefore propose to define a framework for conducting clinically relevant translational biomarker research and seek to establish ideal criteria that can be applied to an infection, systemic inflammation response, organ dysfunction and sepsis biomarkers, which can enable early screening of sepsis, diagnosis of sepsis at the time of clinical suspicion and monitoring of sepsis treatment efficacy.